点击显示 收起
【摘要】
Objective- To compare the effects of intranasal and oral administration of 17ß-estradiol (E 2 ) and norethisterone(acetate) [NET(A)] in healthy postmenopausal women on activated protein C (APC) resistance and other hemostatic parameters associated with venous thrombosis.
Methods and Results- In this 2-center, randomized, double-blind, 1-year trial, 90 postmenopausal women (56.6±4.7 years of age) received daily either an intranasal spray with 175 µg/275 µg E 2 /NET (n=47) or 1 mg/0.5 mg oral E 2 /NETA (n=43). Normalized APC sensitivity ratios (nAPCsr) were determined with a thrombin generation-based APC resistance test. After 1 year, the increase in nAPCsr was smaller in the intranasal than in the oral group: 11% (95% CI, 1% to 22%) versus 53% (95% CI, 37% to 72%). Overall, the decrease in antithrombin and increase in prothrombin fragment 1+2 (F1+2) were smaller and the decrease in free protein S larger in the intranasal compared with the oral group after 1 year. In both groups, the decreases in protein C and prothrombin, and the increase in D -dimer were similar.
Conclusion- Compared with oral E 2 /NETA therapy, intranasal administration of E 2 /NET had less effect on APC resistance and on a number of other parameters associated with venous thrombosis. This observation suggests the possibility of a lower venous thrombosis risk for intranasal E 2 /NET compared with oral therapy.
This randomized, double-blind clinical trial in 90 healthy postmenopausal women compared the effects of intranasal E 2 /NET and oral E 2 /NETA therapy on nAPCsr and on other hemostatic parameters associated with venous thrombosis. Effects in the intranasal group were smaller than in the oral group, which may suggest a lower venous thrombosis risk.
【关键词】 APC resistance hormone therapy intranasal menopause norethisterone venous thrombosis
Introduction
Use of oral postmenopausal hormone therapy (HT) is associated with a 2- to 4-fold increased risk of venous thromboembolism (VTE), 1-3 with the highest risk during the first year of treatment. Although literature regarding possible risk differences between oral and transdermal is conflicting, 1,3-5 the largest case-control study performed so far 3 suggested that women on HT with transdermal estradiol (E 2 ) may not be exposed to an increased risk of VTE (odds ratio , 0.9; 95% CI, 0.5 to 1.6).
In 1993, Dahlbäck et 6 discovered that activated protein C (APC) hardly prolonged the clotting of plasma in members of families with multiple thromboembolic events. This defect, called APC resistance, which was attributed to a mutation in the factor V (FV) gene 7 (FV Leiden), appeared to be a major risk factor of venous thrombosis. 8 Later, it was shown that APC resistance in the absence of FV Leiden is also associated with an increased VTE risk. 9 APC resistance in individuals without FV Leiden is particularly observed during use of combined oral contraceptives (OCs), 10,11 during pregnancy, 11 and while using oral HT. 11-15 Compared with oral HT, HT with transdermal E 2 has a much smaller effect on APC resistance. 14,15
Important other risk factors for the development of VTE are deficiencies in protein C, protein S, and antithrombin and elevated plasma levels of factor VIII (FVIII) and prothrombin. 16 Also, elevated levels of prothrombin fragment 1+2 (F1+2) and D -dimer, both reflecting ongoing coagulation, have been observed in individuals with an increased VTE risk. 17-21
Oral HT induces changes in the plasma levels of coagulation factors that are indicative of the existence of a prothrombotic condition. 22 Although it has been shown that HT with transdermal E 2 has less effect on hemostatic parameters than oral HT, 14,23,24 limited data are available for other forms of nonoral HT.
An intranasal spray has shown to be effective in climacteric symptom relief and a well-tolerated alternative route for E 2 administration (Aerodiol; Servier) 25 with an attractive theoretical advantage of less stimulation of the breast and endometrium, 26 leading to less breakthrough bleeding and mastalgia. 25 In addition to the E 2 -only spray, an intranasal spray for continuous combined 17ß-E 2 plus norethisterone (E 2 /NET) administration has been developed. Because the hepatic metabolism is largely bypassed, it is plausible that, like HT with transdermal E 2, 3 intranasal administration may have limited effect on VTE risk.
Because no data are available on the VTE risk during intranasal HT, we investigated the effect of the intranasal E 2 /NET spray on APC resistance and on the plasma levels of proteins that are associated with an increased risk of VTE. We compared the effects of the intranasal spray with those of low-dose continuous combined oral E 2 /NET acetate (NETA) therapy. This was the objective of a substudy among participants in 2 Dutch centers, in a large international, randomized, double-blind, double-dummy study, with endometrial safety as primary end point.
Materials and Methods
Participants
Healthy postmenopausal women 40 to 75 years of age were recruited from gynecological outpatient clinics of 2 centers in the Netherlands and through advertisements in local newspapers. Specific indications for HT use were not required, but women were willing to participate in the study because of some kind of climacteric symptoms. All women were nonhysterectomized and had their last menstrual period 2 years before inclusion and had serum levels of E 2 <30 pg/mL 30 mIU/mL. All participants had a normal cervical smear and mammography within 12 months before inclusion. A normal transvaginal ultrasound and an endometrial biopsy without hyperplasia or polyps were required, as well as blood tests (lipids, liver enzymes, kidney function, glucose and thyroid-stimulating hormone) without any clinically relevant abnormalities. At screening, all participants had plasma levels of total cholesterol 8.0 mmol/L and triglycerides 3.0 mmol/L. 32 kg/m 2, any contraindication for use of estrogen or progestogen, any ear-nose-throat disease that might interfere with intranasal drug administration, and concomitant use of any treatment for menopausal symptoms, chronic treatment liable to interfere with the coagulation profile, treatment liable to interfere with intranasal administration, enzyme inducers, and systemic vasoconstrictors. The present study was done in a subset of women who were not taking lipid-lowering drugs, and who had either never used HT or had a washout of previous HT of 6 weeks before the baseline visit.
All participants gave written informed consent before participation in the trial, which was conducted in accordance with the ethical principles stated in the Declaration of Helsinki, with Good Clinical Practice, and was approved by central and local institutional review boards.
Study Design
This study was performed in a subgroup of 90 women who were included in 2 centers in the Netherlands, as part of a large international, randomized, double-blind, double-dummy study with 2 parallel treatment arms including 954 women. Eligible women were randomized to either 1 intranasal spray containing a fixed dose of 175 µg E 2 plus 275 µg NET (S21405; Servier) and 1 placebo capsule (intranasal E 2 /NET) or 1 capsule containing 1 mg E 2 plus 0.5 mg NETA (Activelle; Novo Nordisk) and 1 placebo spray (oral E 2 /NETA) daily. Study medication was manufactured, packaged, and labeled by the Institut de Recherches Internationales Servier. Placebo and active treatments were identical in appearance and smell. Centralized computerized subject randomization was done by an Interactive Voice Response System in blocks of 12 (6 active spray and 6 active capsules) per center. Treatment was administered for 52 weeks.
Throughout the whole study period, all participants, clinical investigators, and laboratory personnel were blinded for the study medication. Unblinding was done after all data were collected in the database.
Hemostatic Parameters
For assessment of hemostatic parameters, venous blood samples were taken at baseline and in weeks 12 and 52. After fasting and refraining from smoking for 10 hours and no alcohol intake for 24 hours, blood samples were taken between 8 and 10 AM. After 20 minutes of rest, blood was collected into precooled tubes (Becton Dickinson) containing sodium citrate, theophylline, adenosine, and dipyridamole for FVIII activity or 0.129 mol/L sodium citrate (for protein C, free protein S, antithrombin, F1+2, and D -dimer) or into tubes at room temperature containing 0.129 mol/L sodium citrate (for normalized APC sensitivity ratios , prothrombin, and the test for the FV Leiden mutation). After blood collection, precooled tubes were immediately placed on ice. Within 1 hour after collection, plasma was separated by centrifugation at 2000 g for 30 minutes at 4°C (for blood collected into precooled tubes) or at 20°C (for blood collected into tubes at room temperature). Plasma was divided into aliquots, snap-frozen, and stored at -80°C until analysis. All samples of a given subject were assayed within a single run.
nAPCsr were determined with the endogenous thrombin potential (ETP)-based APC resistance test, 10 in which the effect of APC on the time integral of thrombin generation (ETP) is quantified. A normal plasma pool consisting of 45 men and 27 women (all without OCs/HT/pregnancy) with a mean age of 40±8.9 years was used to normalize the APCsr. In this assay, women (without OCs/HT/pregnancy) generally have a nAPCsr between 1 and 2, whereas the mean nAPCsr of men is <1. Protein C activity was measured with the Coamatic protein C activity kit (Chromogenix), free protein S antigen with the automated latex ligand immunoassay, interleukin test free protein S (Instrumentation Laboratory), antithrombin with the Coamatic antithrombin test (Chromogenix), FVIII activity with the Coatest Factor VIII (Chromogenix), prothrombin with the ecarin activation test, 27 F1+2 with an ELISA (Enzygnost; Dade Behring), and D -dimer with an ELISA (TintElize D -dimer; Biopool). All women were tested for the FV Leiden mutation with a functional test that fully discriminates between homozygous, heterozygous, and noncarriers of the mutation. 28
Serum levels of E 2 and of follicle-stimulating hormone were measured with an electrochemiluminiscence immunoassay (Roche Diagnostics), and serum sex hormone binding globulin levels were measured using an immunoradiometric assay (Orion Diagnostica).
Statistical Analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) 11.5 for Windows (SPSS Inc.). Values of the hemostatic parameters are given as mean±SD or as median (25th to 75th percentile) if skewed. Percentage changes from baseline are given as mean (95% CI) or as geometric mean (95% CI) if the changes had a skewed distribution and for D -dimer as median (25th to 75th percentile) because changes remained skewed after log transformation.
We used standard parametric tests. If variables were skewed, analyses were done after e log transformation. Within-group changes over time were tested using ANOVA for repeated measurements. For between-group comparisons, we used analyses of covariance (ANCOVA) for repeated measurements, with the baseline value of the variable under consideration as covariate. Nonparametric tests were used for comparison between groups of smoking at baseline ( 2 test) and percentage changes in D -dimer (Mann-Whitney U test).
Only data from women, of whom data were available at baseline and 1 other time point, were used for analyses; for AN(C)OVA for repeated measurements, the last observation carried forward procedure for the missing values was applied.
Sample size calculation for this cardiovascular substudy was based on changes in nAPCsr. To find a 35% difference in change in nAPCsr between the groups with an SD in percentage change of 75%, using a power of 80% and an of 5% (2-sided), 37 evaluable women would be required in each group.
Results
Participants
Between September 2001 and June 2002, 125 women were screened in the 2 participating centers, of whom 94 women were randomized. Because 4 women either had no washout from their previous HT (n=3) or used lipid-lowering drugs (n=1), 90 women were eligible for the current substudy. The last patients completed the study in May 2003. No differences in baseline demographic characteristics were found between the 2 groups ( Table 1 ).
TABLE 1. Baseline Characteristics
Two women in the intranasal group discontinued the study versus 10 women in the oral group ( P <0.01; Figure 1 ). Premature study discontinuation was mainly related to the occurrence of an adverse event. No women stopped because of coronary or cerebrovascular events. In the intranasal group, 1 woman discontinued in week 11 because of the occurrence of deep venous thrombosis which, in retrospect, most likely was already present before study entry, and another woman discontinued because of vaginal candidiasis. One woman in the intranasal group was excluded from analyses after week 12 because she started preventive anticoagulant therapy because of a family history of cerebrovascular disease. In the oral group, 1 woman discontinued in week 36 because of clinical symptoms of venous thrombosis, which, however, could not be confirmed ultrasonographically. This woman was 1 of the 4 women who carried the FV Leiden mutation. Furthermore, 1 women in the oral group stopped because of the detection of breast cancer, which, in retrospect, was already present at the mammography before study entry. Other reasons for discontinuation in the oral group were vaginal bleeding, fatigue, lack of efficacy, withdrawal of consent, nasal symptoms, arthralgia, abdominal symptoms, and headache.
Figure 1. Trial profile. n=number of subjects. Intranasal indicates spray containing 175 µg 17ß-E 2 and 275 µg NET; oral, capsule containing 1 mg E 2 and 0.5 mg NETA.
Analyses were based on 86 women (46 in the intranasal and 40 in the oral group) of whom values at baseline and at least at 1 other time point were available.
Hemostatic Parameters
No women in the intranasal group compared with 4 women in the oral group were heterozygous carriers of the FV Leiden mutation. Baseline levels of protein C were lower in the intranasal than in the oral group. At baseline, there were no other significant differences between the 2 groups ( Table 2 ). FV Leiden carriers had higher baseline nAPCsr (range 3.03 to 6.97), which remained higher throughout the study period.
TABLE 2. Plasma Levels of Hemostatic Parameters Associated With Venous Thrombosis
The increase in nAPCsr in the intranasal group was smaller ( P <0.001) than in the oral group. After 52 weeks of treatment, the mean increase of the nAPCsr was 11.2% (95% CI, 1.0%, 22.3%) in the intranasal group and 53.8% (95% CI, 37.1%, 72.5%) in the oral group. Increases in nAPCsr were already apparent after 12 weeks of treatment: 15.5% (95% CI, 8.3%, 23.2%) in the intranasal and 51.3% in the oral group (95% CI, 39.0%, 64.7%) ( Figure 2 ).
Figure 2. Box and whisker plots: boxes represent 25th and 75th percentile with the median; ends of whiskers indicate 10th and 90th percentile of nAPCsr. * P <0.05 vs baseline; P <0.001 vs baseline. Intranasal indicates spray containing E 2 /NET; oral, capsule containing E 2 /NETA.
The decrease in protein C was similar (difference +0.5% [95% CI, -2.8%, 3.8%]) in both groups: -11.1% in the intranasal and -11.6% in the oral group in week 52. Free protein S was more decreased (difference -4.4% [95% CI, -7.8, -0.8]) in the intranasal group: -2.2% in week 52 than in the oral group (+2.2%). For antithrombin, the decrease was less pronounced (difference +4.5% [95% CI, 2.6%, 7.35%]) in the intranasal (-5.7%) than in the oral (10.2%) group ( Figure 3 ).
Figure 3. Percentage change from baseline of the plasma levels of hemostatic parameters in weeks 12 and 52. *Significant difference between the groups; intranasal, spray containing E 2 /NET; oral, capsule containing E 2 /NETA; F1+2, prothrombin fragment 1+2.
No significant difference in change was seen between the groups in FVIII (difference +3.1% [95% CI, -3.9%, 10.2%]), although in week 12, a transient decrease (-3.7%) was observed in the intranasal group. In week 52, prothrombin was equally decreased (difference -0.4% [95% CI, -3.3, 2.5%]) in both groups: -5.2% in the intranasal and -4.8% in the oral group.
The increase in F1+2 in the oral group (19.0% in week 52) was larger (difference +13.2% [95% CI, -2.8%, 29.15]) than the nonsignificant increase in the intranasal group (5.8%). After 52 weeks, the increase in D -dimer did not significantly differ between the groups, although in week 12, the increase was less pronounced in the intranasal group (29.8%) than in the oral group (50.7%; Figure 3 ).
Results did not change when analyses were performed after exclusion of the 4 carriers of the FV Leiden mutation or when the presence of FV Leiden mutation was added as an additional covariate in the ANCOVA (data not shown). Also, exclusion of outliers in the other parameters did not affect the results.
Discussion
At present, there are no reports on the risk of venous thrombosis associated with intranasal HT. The current study is the first to describe the effects of intranasal administration of combined estrogen plus progestogen therapy on hemostatic parameters that are associated with an increased risk of venous thrombosis.
Whereas use of oral postmenopausal HT is known to increase VTE risk, 1,2,29 less is known about the risk of nonoral administration. So far, only 4 case-control studies 1,3-5 have investigated the association between VTE and HT with nonoral (ie, transdermal) E 2. Scarabin et al, 3 the largest of these studies, investigating healthy women who had their first idiopathic venous thrombosis, found no increased risk (OR [95% CI], 0.9 [0.5 to 1.6]) among users of HT with transdermal E 2 compared with the increased risk (OR, 3.5 [1.8 to 6.8]) among users of oral HT. The other 3 studies included very small numbers of cases (2, 5, and 7), and 2 of them 1,4 found a nonsignificant increase in VTE during HT with transdermal E 2, however, smaller than for oral HT. 1
Intranasally administered E 2 is rapidly absorbed and induces very steep and short peaks in serum E 2 levels. Because of the lack of a first-pass liver effect, intranasally administered hormones may have less effect on plasma levels of coagulation factors than orally administered hormones. Hence, like has been suggested for HT with transdermal E 2, 3 HT with intranasal E 2 may be associated with a lower risk of venous thrombosis. The dosages we compared have shown similar exposure to E 2 30 and NET, the active hormone of NETA (unpublished data, 2001).
Until now, the effect of intranasal E 2 on hemostatic parameters has been reported in only 1 study. 25 Given with oral dydrogesterone in a sequentially combined fashion, 24 weeks of intranasal 300 µg E 2 did not show significant changes from baseline in antithrombin or D -dimer. 25
Increased resistance to APC is associated with an increased VTE risk. 8,9 APC resistance was measured with the ETP-based APC resistance test. 10 This is a functional assay that, in contrast to the commonly used activated partial thrombroplastin time-based APC resistance test, 6 is very sensitive for changes in the levels of sex steroid hormones. 10-15
In this 1 year, randomized, double-blind study the increase in nAPCsr during intranasal E 2 /NET therapy (11%) was significantly less than the increase observed during oral E 2 /NETA therapy (54%). With respect to oral E 2 /NETA therapy, our observations are in agreement with placebo-controlled studies with various oral HT regimens 12-15 including E 2 /NETA therapy. 12 Literature on the effect of nonoral HT on APC resistance is only available for transdermal therapy. Compared with placebo and oral HT, 14,15 HT with transdermal E 2 caused a smaller increase 14 or had no significant effect 15 on the nAPCsr.
Our study further shows that, among the antithrombotic proteins, protein C was similarly decreased in both groups, and free protein S showed a larger decrease and antithrombin a smaller decrease in the intranasal E 2 /NET compared with the oral E 2 /NETA group. For the comparison between oral HT and HT with transdermal E 2, previous studies generally reported no significant difference in changes in antithrombotic proteins. 14,15,23 During oral HT plasma levels of anticoagulant proteins are significantly reduced, 14,31-33 although in some studies, a transient decrease or no change of protein S was observed. 15,31 During HT with transdermal E 2, both decreases 14,34 and no changes 15,23,34 of anticoagulant proteins were reported.
In the current study, intranasal E 2 /NET and oral E 2 /NETA decreased the plasma level of prothrombin, increased D -dimer to a similar extent, and had no effect on the FVIII level. A significant increase of F1+2 was only observed during oral E 2 /NETA therapy. Our findings with oral E 2 /NETA are largely in line with previous randomized studies in which HT using oral and transdermal E 2 were compared 14,23,35 and with placebo-controlled studies in which the effect of oral E 2 /NETA was investigated. 31,33 During transdermal E 2, either unopposed, 14,24,35 or combined with transdermal 36 or oral progestogen, 23 slight increases or no effect on FVIII, prothrombin, F1+2, or D -dimer were found.
The significantly smaller increase in nAPCsr in the intranasal group might reflect a lower risk for the development of VTE during intranasal HT. This would be in line with the observations that HT using transdermal E 2 induces a relatively small increase in the nAPCsr 14,15 and may not increase the risk of VTE. 3 Also in OC users, there appears to be a good correlation between the nAPCsr and the risk of venous thrombosis. 10,11 Women who use second-generation OCs are exposed to a lower thrombotic risk than third-generation pill users, and their plasma is less APC resistant than that of third-generation pill users. 10,11
One of the strengths of our study is the randomized, double-blind study design and the 1 year duration, including the measurement of short-term effects after 3 months of therapy. The study also has limitations. We did not include an untreated or placebo control group. However, we compared the effects of the new intranasal spray with a well-studied reference product, the effects of which were found to be comparable with those observed in placebo-controlled studies. The study was not designed to detect differences in venous thombotic risk or a possible interaction between FV Leiden and HT use.
In conclusion, in this study, in healthy postmenopausal women, intranasal continuous combined E 2 /NET therapy showed smaller changes in nAPCsr, antithrombin, and F1+2 than oral E 2 /NETA therapy. This might be indicative for a lower VTE risk during intranasal E 2 /NET therapy when compared with oral therapy.
Acknowledgments
We thank all women who participated in the study. C. Klipping, MD, Dinox Medical Investigations, Nijmegen, and M.O. Verhoeven, MD, and T.E. Vogelvang, MD, PhD, VU University Medical Center, Amsterdam, are acknowledged for logistical and technical assistance, and we thank E.J.P. Magdeleyns, Department of Biochemistry, Maastricht University, and A. Kok, Department of Biochemistry, VU University Medical Center, Amsterdam, for laboratory management.
Source of Funding
This study was supported by a research grant from the Institut de Recherches Internationales Servier to the Biocare Foundation (grant no 01-049).
Disclosures
None.
【参考文献】
Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996; 348: 977-980.
Writing Group for the Women?s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women?s Health Initiative randomized controlled trial. J Am Med Assoc. 2002; 288: 321-333.
Scarabin PY, Oger E, Plu-Bureau. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 362: 428-432.
Perez GS, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997; 314: 796-800.
Høibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism-a population-based case-control study. Thromb Haemost. 1999; 82: 1218-1221.
Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993; 90: 1004-1008.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369: 64-67.
Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993; 342: 1503-1506.
de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999; 93: 1271-1276.
Rosing J, Middeldorp S, Curvers J, Thomassen MC, Nicolaes GA, Meijers JC, Bouma BN, Büller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet. 1999; 354: 2036-2040.
Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost. 2002; 88: 5-11.
Høibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 2001; 115: 415-420.
Post MS, Rosing J, van der Mooren MJ, Zweegman S, van Baal WM, Kenemans P, Stehouwer CD. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol. 2002; 119: 1017-1023.
Post MS, Thomassen MC, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003; 23: 1116-1121.
Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall JF, Aiach M, Scarabin PY, Mottier D. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003; 23: 1671-1676.
Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999; 353: 1167-1173.
Cofrancesco E, Cortellaro M, Corradi A, Ravasi F, Bertocchi F. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery. Thromb Haemost. 1997; 77: 267-269.
Zoller B, Holm J, Svensson P, Dahlbäck B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost. 1996; 75: 270-274.
Gouin-Thibault I, Arkam R, Nassiri S, de la TA, Conard J, Horellou MH, Elalamy I, Samama MM. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thromb Res. 2002; 107: 7-11.
Andreescu AC, Cushman M, Rosendaal FR. D -dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. Thromb Haemost. 2002; 87: 47-51.
Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR. Fibrin fragment D -dimer and the risk of future venous thrombosis. Blood. 2003; 101: 1243-1248.
Cano A, van Baal WM. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas. 2001; 40: 17-38.
Scarabin PY, Alhenc-Gelas M, Plu-Bureau, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997; 17: 3071-3078.
Post MS, van der Mooren MJ, van Baal WM, Blankenstein MA, Merkus HM, Kroeks MV, Franke HR, Kenemans P, Stehouwer CD. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol. 2003; 189: 1221-1227.
Mattsson LA, Christiansen C, Colau JC, Palacios S, Kenemans P, Bergeron C, Chevallier O, Von Holst T, Gangar K. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol. 2000; 182: 545-552.
Kenemans P, Genazzani AR, Palacios S, Schneider HP. Pulsed estrogen exposure selectively modulates tissue response: a hypothesis. Gynecol Endocrinol. 2004; 18: 159-164.
Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980; 255: 274-283.
Nicolaes GA, Thomassen MC, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemost. 1996; 76: 404-410.
Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med. 2000; 132: 689-696.
Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet. 1999; 24: 265-271.
Høibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial. Thromb Haemost. 2001; 85: 775-781.
Salobir BG, Keber I, Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril. 2002; 78: 1178-1183.
Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG. 2003; 110: 541-547.
The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost. 1996; 75: 476-480.
Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001; 85: 619-625.
Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol. 2004; 124: 802-808.
作者单位：Project “Aging Women“ and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU), Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, the Netherlands (M.H., P.K., M.J.v.d.M.), and Radboud University Nijmegen Medical Centre, Nijmegen (D.D.M.B.